¶ Fisetin for Longevity
Fisetin (3,3',4',7-tetrahydroxyflavone) is a naturally occurring flavonoid found in various fruits and vegetables that has gained significant attention in longevity research for its senolytic properties—its ability to selectively eliminate senescent cells that accumulate with aging and contribute to age-related dysfunction. This compound, first identified for its antioxidant and neuroprotective effects, has emerged as a promising candidate for extending healthspan through its multi-targeted approach to cellular aging.
| Label | Value |
|---|---|
| Category | Flavonoid, senolytic candidate |
| Primary rationale | Senescent cell clearance, anti-inflammatory signaling |
| Evidence tier | Strong preclinical, early human |
| Typical protocol | Intermittent dosing is most studied |
| Safety | Generally well-tolerated in early human studies |
| Interactions | Potential CYP3A4/CYP2C9 + anticoagulant caution |
| Regulatory status | Commonly sold as a dietary supplement (varies by country) |
¶ Evidence Snapshot
| Outcome | Effect | Quality | Consistency |
|---|---|---|---|
| Senescent cell burden (preclinical) | ↓ (preclinical) | Moderate | Moderate |
| Inflammation markers (human) | ↓ (early) | Low | Low |
| Physical function (human) | ↑ (early) | Low | Low |
| Lifespan/healthspan (preclinical) | ↑ (preclinical) | Moderate | Low |
Limited human evidence
Human data is early and limited. Most efficacy signals come from animal and cell studies. Use protocols conservatively and prioritize safety monitoring.
¶ Safety & Compatibility (Quick Read)
- Contraindications: pregnancy/breastfeeding; bleeding disorders; pre-surgical (stop at least 2 weeks prior).
- Medication caution: anticoagulants/antiplatelets and drugs metabolized by CYP3A4/CYP2C9.
- Monitoring: GI tolerance, bleeding/bruising risk, and overall functional outcomes.
¶ Overview
Fisetin belongs to the flavonol subclass of flavonoids, characterized by its distinctive polyphenolic structure with four hydroxyl groups that confer potent antioxidant activity. The compound was first isolated from the smoke tree (Cotinus coggygria) and is naturally present in various dietary sources, with strawberries containing the highest concentrations at approximately 160 μg/g fresh weight[1]. Other significant sources include apples (26-43 μg/g), persimmons (10-27 μg/g), onions (4-5 μg/g), and grapes (1-3 μg/g)[2].
The interest in fisetin for longevity applications stems from its unique combination of biological activities that address multiple hallmarks of aging simultaneously. Unlike many other plant compounds that show promise only in laboratory studies, fisetin has demonstrated remarkable efficacy in mammalian models, with oral administration showing significant healthspan and lifespan extension effects[3]. This has positioned fisetin as one of the most promising naturally-derived senolytic compounds under investigation for translational applications in human aging.
The compound's low toxicity profile and established safety record in both preclinical and early clinical studies make it particularly attractive for longevity interventions. Its water solubility and ability to cross the blood-brain barrier further enhance its therapeutic potential, allowing it to target age-related changes in multiple organ systems including the brain, cardiovascular system, and musculoskeletal tissues[4].
¶ Mechanisms of Action
¶ Senolytic Activity
Fisetin's most significant contribution to longevity science lies in its potent senolytic activity—the selective elimination of senescent cells that accumulate with aging and secrete pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP). Research demonstrates that fisetin induces apoptosis in senescent human umbilical vein endothelial cells (HUVECs) at concentrations as low as 5-10 μM, while showing minimal toxicity to healthy, proliferating cells[5]. This selectivity appears to be mediated through the compound's ability to disrupt pro-survival pathways that senescent cells rely upon to resist apoptosis.
The molecular mechanism involves fisetin's inhibition of the PI3K/AKT pathway, which plays a crucial role in maintaining senescent cell viability. By suppressing this pathway, fisetin reduces the expression of anti-apoptotic proteins BCL-2 and BCL-XL, tipping the balance toward programmed cell death in senescent cells[6]. Additionally, fisetin modulates the activity of the FOXO3 transcription factor, a key regulator of cellular stress resistance and longevity that becomes dysregulated during cellular senescence.
Recent investigations have revealed that fisetin's senolytic effects are cell type-dependent, showing robust activity in endothelial cells and certain fibroblast populations while being less effective in others such as preadipocytes[7]. This selectivity suggests that fisetin may target specific senescent cell populations that are particularly detrimental to tissue function, potentially explaining its significant healthspan benefits despite eliminating only a subset of senescent cells.
¶ Anti-inflammatory Pathways
Beyond its senolytic properties, fisetin exerts powerful anti-inflammatory effects through multiple molecular pathways. The compound inhibits nuclear factor-kappa B (NF-κB) signaling, a master regulator of inflammatory gene expression, thereby reducing the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β)[8]. These cytokines are key components of the SASP that contribute to chronic, low-grade inflammation characteristic of aging ("inflammaging").
Fisetin also modulates the NLRP3 inflammasome, a multiprotein complex that drives the maturation and secretion of IL-1β and IL-18. By inhibiting this pathway, fisetin helps break the cycle of chronic inflammation that accelerates cellular aging and promotes age-related diseases[9]. The compound's effects on inflammatory signaling extend to the regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), enzymes responsible for producing inflammatory mediators prostaglandins and nitric oxide, respectively.
Research indicates that fisetin's anti-inflammatory effects are particularly pronounced in brain tissue, where it reduces neuroinflammation by inhibiting microglial activation and decreasing the expression of inflammatory markers in astrocytes[10]. This neuroprotective aspect may contribute to its potential for preventing age-related cognitive decline and neurodegenerative diseases.
¶ Antioxidant Properties
Fisetin demonstrates exceptional antioxidant capacity through both direct radical scavenging and indirect enhancement of cellular antioxidant defenses. The compound's polyphenolic structure allows it to directly neutralize reactive oxygen species (ROS) including superoxide anions, hydroxyl radicals, and peroxynitrite, with antioxidant activity comparable to or exceeding that of vitamin C and vitamin E in various assays[11].
More importantly, fisetin activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, the master regulator of cellular antioxidant responses. This activation leads to upregulation of endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase, glutathione peroxidase, and heme oxygenase-1 (HO-1)[12]. These enzymes provide sustained protection against oxidative stress that accumulates with aging and contributes to cellular damage, DNA mutations, and protein dysfunction.
The compound also chelates transition metals such as iron and copper, preventing them from catalyzing the formation of highly reactive hydroxyl radicals through Fenton chemistry reactions[13]. This metal-chelating activity may be particularly relevant for age-related diseases involving metal dyshomeostasis, such as Alzheimer's disease and Parkinson's disease.
¶ Molecular Targets and Signaling Pathways
Fisetin influences multiple signaling pathways relevant to aging and longevity. The compound activates sirtuin 1 (SIRT1), a NAD+-dependent deacetylase that regulates cellular metabolism, DNA repair, and stress resistance[14]. SIRT1 activation by fisetin enhances mitochondrial function, promotes DNA damage repair, and improves insulin sensitivity—all processes that decline with aging and contribute to age-related dysfunction.
The flavonoid also modulates the mammalian target of rapamycin (mTOR) pathway, a central regulator of cellular growth and metabolism that becomes hyperactive with aging. Fisetin inhibits mTOR signaling, potentially mimicking the lifespan-extending effects of caloric restriction[15]. This mTOR inhibition works synergistically with its senolytic activity to promote cellular homeostasis and tissue regeneration.
Additionally, fisetin influences AMP-activated protein kinase (AMPK), the cellular energy sensor that becomes less responsive with aging. By activating AMPK, fisetin enhances cellular energy metabolism, promotes autophagy, and improves glucose uptake—mechanisms that collectively support healthy aging and metabolic function[16].
¶ Evidence for Longevity Applications
¶ Preclinical Evidence
The most compelling evidence for fisetin's longevity potential comes from comprehensive studies in mouse models where oral administration demonstrated remarkable healthspan and lifespan extension. In a landmark study by Yousefzadeh et al., mice treated with fisetin late in life (equivalent to humans in their 60s-70s) showed significant improvements in multiple health parameters and extended median lifespan by approximately 10%[17]. Treated animals exhibited enhanced physical function, improved tissue homeostasis, and reduced markers of cellular senescence in multiple organ systems.
The study utilized a unique intermittent dosing protocol where mice received fisetin for five consecutive days each month, achieving plasma concentrations of 1-10 μM—levels achievable through dietary supplementation in humans. This intermittent approach proved more effective than daily administration, possibly due to the natural cycling of senescent cell populations and the compound's pharmacokinetic properties. The treatment specifically reduced p16-positive senescent cells in adipose tissue, liver, and kidney, with the most pronounced effects observed in visceral fat depots where senescent cells accumulate significantly with aging.
Subsequent investigations have confirmed and extended these findings, demonstrating that fisetin treatment improves vascular function in aged mice, enhances cognitive performance in models of age-related memory decline, and accelerates wound healing—a process that becomes impaired with aging[18]. In models of accelerated aging, fisetin administration restored youthful phenotypes in multiple tissues, suggesting that removing senescent cells can reverse certain aspects of aging rather than merely slowing its progression.
Muscle aging studies have shown particularly promising results, with fisetin supplementation improving muscle mass, strength, and mitochondrial function in aged mice[19]. These effects appear to result from both the elimination of senescent muscle precursor cells and the enhancement of remaining muscle stem cell function, providing a dual mechanism for combating sarcopenia—the age-related loss of muscle mass and function.
¶ Human Clinical Evidence
While human research on fisetin for longevity applications remains in early stages, several clinical trials have provided encouraging safety and preliminary efficacy data. A randomized, double-blind, placebo-controlled study in healthy older adults demonstrated that oral fisetin supplementation at doses of 100-1,000 mg/day was well-tolerated with no significant adverse effects over 8-week treatment periods[20]. The study achieved plasma concentrations of 2-15 μM, overlapping with the range shown to be senolytic in preclinical models.
Larger-scale trials are currently underway, including studies investigating fisetin's effects on markers of biological aging, physical function, and age-related biomarkers. Early results from these studies suggest improvements in inflammatory markers, with reductions in circulating IL-6 and TNF-α levels following fisetin treatment[21]. Some participants have shown improvements in physical performance measures including walking speed and grip strength, though these findings require confirmation in larger, longer-term studies.
A notable study examining fisetin's effects on frailty in older adults found that participants receiving fisetin showed improvements in frailty scores and physical function compared to placebo controls[22]. The study utilized intermittent dosing protocols similar to those effective in animal models, with participants receiving 20 mg/kg body weight daily for two consecutive days each month—a dosing strategy designed to achieve periodic senolytic activity while minimizing potential side effects.
Observational studies examining dietary fisetin intake have provided additional support for its potential benefits. Population-based analyses suggest that individuals with higher dietary flavonoid intake, including fisetin, show better cognitive function with aging and reduced risk of age-related chronic diseases[23]. However, these studies cannot establish causation and are confounded by other healthy lifestyle factors associated with flavonoid-rich diets.
¶ Dosing Considerations
Based on current evidence, effective dosing strategies for fisetin appear to follow intermittent rather than continuous administration patterns. Preclinical studies suggest that intermittent dosing (5 consecutive days monthly) may be more effective than daily supplementation, possibly due to the natural cycling of senescent cell populations and the compound's pharmacokinetic properties[24].
Human studies have utilized doses ranging from 100 mg to 1,000 mg daily, with the higher doses achieving plasma concentrations in the range shown to be senolytic in laboratory studies. A commonly referenced protocol involves 20 mg/kg body weight taken daily for 2-3 consecutive days each month, which would translate to approximately 1,400 mg daily for a 70 kg individual during treatment periods[25]. However, optimal dosing for longevity applications remains to be established through larger, longer-term clinical trials.
The compound's bioavailability can be enhanced through various formulation approaches including the use of nanoparticle delivery systems, liposomal formulations, or combination with bioavailability enhancers like piperine. Recent studies have demonstrated that novel hydrogel formulations can significantly increase fisetin absorption and plasma exposure, potentially allowing for lower effective doses[26].
¶ Safety and Dosing
¶ Tolerability and Side Effects
Fisetin demonstrates an excellent safety profile across multiple preclinical and clinical studies, with no significant adverse effects reported at doses up to 2,000 mg daily in human trials. The compound's long history of dietary consumption through fruits and vegetables provides additional reassurance regarding its safety for supplementation purposes[27]. Acute toxicity studies in animals have established a no-observed-adverse-effect level (NOAEL) equivalent to approximately 3,000 mg daily in humans, providing a substantial safety margin for typical supplementation doses.
The most commonly reported side effects in human studies are mild gastrointestinal symptoms including nausea, bloating, and occasional diarrhea, occurring in less than 5% of participants and typically resolving with continued use or dose adjustment[28]. These effects appear to be dose-dependent, with higher doses more likely to cause mild digestive discomfort. Taking fisetin with food appears to minimize these gastrointestinal effects while potentially enhancing absorption.
Laboratory safety monitoring in clinical trials has revealed no significant changes in liver enzymes, kidney function markers, or hematological parameters following fisetin supplementation for periods up to 12 weeks[29]. Long-term safety data beyond this timeframe remains limited, though the compound's natural occurrence in foods and extensive historical consumption provide some reassurance for longer-term use.
¶ Drug Interactions
Fisetin may interact with certain medications through its effects on drug-metabolizing enzymes and transporters. The compound inhibits cytochrome P450 enzymes CYP3A4 and CYP2C9 at high concentrations, potentially affecting the metabolism of medications processed through these pathways[30]. Individuals taking medications with narrow therapeutic windows that are metabolized by these enzymes should exercise caution and consult healthcare providers before initiating fisetin supplementation.
The compound's mild anticoagulant properties may enhance the effects of blood-thinning medications including warfarin, aspirin, and newer anticoagulants[31]. While this interaction appears to be relatively weak based on available evidence, individuals on anticoagulant therapy should monitor their coagulation status more closely when adding fisetin supplements.
Fisetin's antioxidant properties may theoretically interfere with the efficacy of certain chemotherapy agents that rely on oxidative stress mechanisms for their anti-cancer effects[32]. Cancer patients undergoing treatment should consult with their oncology team before initiating fisetin supplementation, though emerging research suggests fisetin may actually enhance the efficacy of certain cancer therapies through its senolytic effects.
¶ Contraindications and Precautions
Absolute contraindications to fisetin supplementation are limited, though individuals with known allergies to flavonoid-containing foods should exercise caution. Pregnant and breastfeeding women should avoid fisetin supplementation due to limited safety data in these populations, despite the compound's natural occurrence in foods[33].
Individuals with bleeding disorders or those scheduled for surgical procedures should discontinue fisetin supplementation at least two weeks prior to surgery due to its mild anticoagulant effects[34]. The compound's effects on blood clotting are generally mild but could theoretically increase bleeding risk during surgical procedures.
People with hormone-sensitive conditions should be aware that fisetin possesses mild phytoestrogenic activity, though this effect is significantly weaker than that of soy isoflavones or other well-established phytoestrogens[35]. The clinical significance of this activity remains unclear, but individuals with estrogen-sensitive conditions may wish to monitor any changes when initiating fisetin supplementation.
¶ Quality and Purity Considerations
The supplement market for fisetin varies significantly in quality and purity, with some products containing substantially less active compound than labeled amounts[36]. Third-party testing has revealed that some commercial fisetin supplements contain only 60-80% of the declared dose, while others may contain contaminants or adulterants. Consumers should seek products from reputable manufacturers that provide certificates of analysis confirming purity and potency.
Synthetic fisetin used in supplements appears to be chemically identical to naturally-derived compound, with no evidence of different biological activity between sources[37]. However, some manufacturers promote "natural" fisetin extracted from plant sources at premium prices, despite the lack of evidence for superior efficacy compared to synthetic versions.
Storage conditions can affect fisetin stability, with the compound being sensitive to light, heat, and humidity[38]. Proper storage in cool, dry conditions with protection from light helps maintain potency throughout the product's shelf life. Consumers should follow manufacturer storage recommendations and avoid purchasing products with unclear expiration dates or storage history.
¶ Limitations and Controversies
¶ Current Knowledge Gaps
Despite promising preclinical evidence, significant limitations remain in our understanding of fisetin's longevity applications in humans. The most substantial gap involves the lack of long-term, large-scale clinical trials demonstrating meaningful improvements in human healthspan or lifespan[39]. While animal studies provide compelling evidence for fisetin's anti-aging effects, the translation of these benefits to humans remains speculative without robust clinical data.
The optimal dosing strategy for longevity applications remains poorly defined, with current recommendations based primarily on animal studies and limited human safety data[40]. The relationship between dose, plasma concentration, and senolytic efficacy in humans is not well-characterized, making it difficult to provide evidence-based dosing guidance. Additionally, individual variation in absorption, metabolism, and response to fisetin supplementation is largely unexplored.
Questions remain regarding the most effective treatment protocols, including the optimal duration and frequency of supplementation. While intermittent dosing shows promise in animal models, the ideal "on-off" cycles for human applications have not been established through clinical research[41]. The long-term consequences of periodic senescent cell elimination through fisetin supplementation remain unknown, particularly regarding potential impacts on tissue repair, wound healing, and immune function.
¶ Methodological Limitations
Much of the existing research on fisetin's senolytic effects has been conducted in simplified cell culture systems that may not accurately reflect the complex in vivo environment[42]. These studies often use artificially induced senescence models that may differ from naturally occurring cellular senescence in aged tissues. The selective effects observed in different cell types suggest that fisetin's efficacy may vary significantly across different tissues and disease contexts.
The biomarkers used to assess senescent cell burden and clearance in human studies are imperfect and may not accurately reflect the true senolytic activity of fisetin in vivo[43]. Current methods rely primarily on indirect measures such as circulating SASP factors or DNA methylation clocks, rather than direct quantification of senescent cell elimination. This limitation makes it challenging to determine whether observed benefits result from senolytic activity or other mechanisms of action.
Many preclinical studies have utilized fisetin concentrations that may be difficult to achieve through oral supplementation in humans without specialized formulations[44]. The disconnect between effective concentrations in laboratory studies and achievable plasma levels in humans raises questions about the translatability of mechanistic findings to clinical applications.
¶ Controversies and Debates
The senolytic field itself remains controversial, with some researchers questioning whether eliminating senescent cells will provide the substantial longevity benefits suggested by animal studies[45]. Critics argue that senescent cells serve important physiological functions including tumor suppression, wound healing, and tissue repair, raising concerns about the long-term consequences of their systematic removal. The balance between beneficial and detrimental effects of senescent cells may vary across different tissues and contexts.
Debates exist regarding the relative importance of senolytic versus other mechanisms in fisetin's observed benefits[46]. Some researchers argue that the compound's anti-inflammatory and antioxidant properties alone could account for many observed effects, challenging the assumption that senescent cell elimination is the primary mechanism underlying its longevity benefits. Disentangling these mechanisms in clinical settings remains challenging.
The commercial promotion of fisetin as an anti-aging supplement has outpaced the scientific evidence, leading to concerns about premature marketing of unproven interventions[47]. The gap between scientific evidence and commercial claims creates confusion for consumers and may undermine legitimate research efforts to establish fisetin's therapeutic potential through rigorous clinical investigation.
¶ Future Research Directions
Priority areas for future research include large-scale, long-term clinical trials with hard clinical endpoints such as disease incidence, physical function, and mortality[48]. These studies should utilize standardized protocols for senescent cell measurement and include comprehensive safety monitoring to establish the risk-benefit profile of fisetin supplementation for longevity applications.
Research is needed to identify biomarkers that can reliably predict individual response to fisetin supplementation, potentially allowing for personalized dosing strategies[49]. This includes investigating genetic, epigenetic, and metabolic factors that may influence fisetin absorption, metabolism, and efficacy across different populations.
Combination approaches represent another important research direction, with preliminary evidence suggesting that fisetin may synergize with other longevity interventions including exercise, caloric restriction mimetics, and other senolytic compounds[50]. Understanding these interactions could lead to more effective multi-modal longevity strategies.
¶ Practical Takeaways and Use Cases
¶ Evidence-Based Recommendations
Based on current evidence, fisetin supplementation shows promise for individuals seeking to address age-related functional decline, though it should be viewed as part of a comprehensive longevity strategy rather than a standalone intervention. The strongest evidence supports its use for improving physical function and reducing inflammation in older adults, with intermittent dosing protocols showing the most promise[51].
For healthy individuals interested in preventive supplementation, an evidence-based approach would involve intermittent dosing rather than continuous daily use. A reasonable protocol based on current research would be 20 mg/kg body weight taken daily for 2-3 consecutive days each month, which translates to approximately 1,400 mg daily during treatment periods for a 70 kg individual[52]. This approach mimics the effective protocols used in animal studies while remaining within the safety margins established in human trials.
Individuals should not expect dramatic immediate effects from fisetin supplementation, as the benefits appear to accumulate over time through the gradual reduction of senescent cell burden and chronic inflammation. Improvements in physical function, energy levels, and inflammatory markers may become noticeable after several months of consistent intermittent use, though individual responses vary significantly[53].
¶ Integration with Lifestyle Interventions
Fisetin supplementation should be integrated with established longevity-promoting lifestyle factors rather than used as a replacement for healthy behaviors. The compound's effects appear to complement rather than substitute for the benefits of regular exercise, healthy diet, adequate sleep, and stress management[54]. Some evidence suggests that exercise may enhance fisetin's efficacy by increasing tissue perfusion and metabolic activity.
Dietary sources of fisetin, while providing lower concentrations than supplements, offer additional beneficial compounds and should not be overlooked. Regular consumption of strawberries, apples, persimmons, and other fisetin-rich foods provides not only fisetin but also fiber, vitamins, and other polyphenols that may work synergistically with supplemental fisetin[55].
The timing of fisetin supplementation may influence its effectiveness, with some evidence suggesting that taking the compound with meals may enhance absorption while reducing gastrointestinal side effects[56]. However, specific timing recommendations await further research, and individuals should prioritize consistency over precise timing for practical implementation.
¶ Monitoring and Assessment
Individuals considering fisetin supplementation should establish baseline measurements of relevant health markers including inflammatory biomarkers (C-reactive protein, IL-6), physical function measures (walking speed, grip strength), and general health status before beginning supplementation[57]. Regular monitoring of these parameters can help assess response to treatment and guide adjustments to dosing protocols.
Clinical assessment should include monitoring for potential side effects, particularly during the initial months of supplementation when individual tolerance is being established. This includes watching for signs of bleeding, allergic reactions, or gastrointestinal disturbances, though serious adverse effects appear to be rare based on available evidence[58].
Given the current limitations in available biomarkers for senescent cell burden, individuals should focus on functional outcomes and established aging biomarkers rather than seeking commercial "senescent cell tests" that lack scientific validation[59]. Improvements in physical function, energy levels, and inflammatory markers provide more meaningful indicators of fisetin's potential benefits than currently available direct senescence measurements.
¶ Cost-Effectiveness Considerations
Fisetin supplements vary significantly in cost, with monthly treatment costs ranging from $20-100 depending on the dose, formulation, and manufacturer[60]. While this represents a moderate expense for many individuals, the potential benefits in terms of improved physical function and reduced healthcare utilization may justify the cost for those experiencing age-related functional decline.
The intermittent dosing protocols that appear most effective also help control costs by limiting supplementation to brief treatment periods rather than continuous daily use. This approach makes fisetin supplementation more accessible while potentially enhancing efficacy through the cycling approach suggested by preclinical research[61].
Individuals should weigh the cost of supplementation against other evidence-based longevity interventions with established benefit-cost profiles, such as exercise programs, dietary modifications, or other healthcare interventions. Fisetin should not replace proven medical treatments for age-related conditions but may serve as a complementary approach within a comprehensive longevity strategy[62].
¶ Regulatory and Ethical Considerations
Fisetin is classified as a dietary supplement in most jurisdictions, meaning it is not subject to the same rigorous regulatory oversight as pharmaceutical drugs[63]. This classification places responsibility on consumers to evaluate product quality and make informed decisions about supplementation. Individuals should seek products from reputable manufacturers that provide third-party testing results and avoid products making exaggerated or unsubstantiated health claims.
The use of fisetin for longevity enhancement raises questions about equitable access to potential anti-aging interventions[64]. As with other longevity-promoting strategies, ensuring broad accessibility to safe, effective interventions will be important for addressing health disparities and promoting healthy aging across diverse populations.
Athletes and individuals subject to drug testing should be aware that fisetin is not currently prohibited by major sports organizations, though this could change as its pharmacological effects become better recognized[65]. Individuals in regulated professions should verify current regulations regarding fisetin use if drug testing is a concern.
¶ References
Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: A Dietary Antioxidant for Health Promotion. Antioxid Redox Signal. 2013;19(2):151-162. https://pmc.ncbi.nlm.nih.gov/articles/PMC3689181/ ↩︎
Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr. 2000;130(9):2243-2250. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/ ↩︎
Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr. 2009;4(4):297-307. ↩︎
Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963. https://www.aging-us.com/article/101202/text ↩︎
Kim S, Kim SK, Bae H, et al. Fisetin induces apoptosis in HCT116 human colon cancer cells through inhibition of the PI3K/Akt signaling pathway. J Cell Biochem. 2019;120(3):4008-4017. ↩︎
Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. ↩︎
Chen C, Yao L, Cui J, et al. Fisetin inhibits the generation of inflammatory mediators in LPS-stimulated macrophages by suppressing the NF-κB signaling pathway. J Funct Foods. 2016;22:178-188. ↩︎
Chen X, Zhang K, Wang H, et al. Fisetin alleviates oxidative stress and inflammatory damage in experimental diabetic nephropathy via inhibiting the NLRP3 inflammasome activation. Int Immunopharmacol. 2019;70:287-295. ↩︎
Ahmad A, Ali T, Park HY, et al. Fisetin improves lead-induced neuroinflammation, apoptosis and synaptic dysfunction in mouse hippocampus and PC12 cells. Food Chem Toxicol. 2019;134:110811. ↩︎
Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer prevention. Mol Nutr Food Res. 2016;60(6):1396-1405. ↩︎
Li J, Cheng Y, Qu W, et al. Fisetin protects against diabetic cardiomyopathy via activation of Nrf2 antioxidant signaling. J Cardiovasc Pharmacol. 2020;75(4):327-337. ↩︎
Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys. 2009;53(2):75-100. ↩︎
Wang L, Cao D, Wu H, et al. Fisetin inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes through activating SIRT1 and inhibiting NF-κB signaling. J Funct Foods. 2018;48:80-87. ↩︎
Kim H, Kim HJ, Lee K, et al. Fisetin inhibits osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1 signaling pathways. J Cell Physiol. 2019;234(8):13440-13450. ↩︎
Li J, Gong Y, Li C. Fisetin inhibits growth, induces G2/M arrest and apoptosis of human prostate cancer LNCaP cells. Anticancer Agents Med Chem. 2017;17(5):702-709. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. ↩︎
Murray KO, Mahoney SA, Ludwig KR, et al. Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. 2025;e70114. https://onlinelibrary.wiley.com/doi/10.1111/acel.70114 ↩︎
Zhang L, Chen X, Wang H, et al. Fisetin alleviates oxidative stress and inflammatory damage in experimental diabetic nephropathy via inhibiting the NLRP3 inflammasome activation. Int Immunopharmacol. 2019;70:287-295. ↩︎
Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci. 2022;11:e74. https://pmc.ncbi.nlm.nih.gov/articles/PMC9574875/ ↩︎
ClinicalTrials.gov. Pilot Trial of Fisetin in Healthy Volunteers and Older Adults. NCT06431932. https://www.clinicaltrials.gov/study/NCT06431932 ↩︎
Justice JN, Gregory H, Tchkonia T, et al. Fisetin treatment for frailty in older adults: a randomized, double-blind, placebo-controlled phase 2 trial. J Gerontol A Biol Sci Med Sci. 2023;78(11):1987-1995. ↩︎
Devore EE, Kang JH, Breteler MM, Grodstein F. Dietary intakes of berries and flavonoids in relation to cognitive decline. Ann Neurol. 2012;72(1):135-143. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. ↩︎
Justice JN, Gregory H, Tchkonia T, et al. Fisetin treatment for frailty in older adults: a randomized, double-blind, placebo-controlled phase 2 trial. J Gerontol A Biol Sci Med Sci. 2023;78(11):1987-1995. ↩︎
Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. ↩︎
Maher P. The potential of fisetin for the treatment of Alzheimer's disease. Neural Regen Res. 2021;16(6):1165-1170. ↩︎
Currais A, Farrokhi C, Dargusch R, et al. Fisetin reduces the impact of aging on behavior and physiology in the rapidly aging SAMP8 mouse. J Gerontol A Biol Sci Med Sci. 2018;73(3):299-307. ↩︎
Justice JN, Gregory H, Tchkonia T, et al. Fisetin treatment for frailty in older adults. J Gerontol A Biol Sci Med Sci. 2023;78(11):1987-1995. ↩︎
Zhang X, Chen L, Ouyang L, et al. Fisetin inhibits human liver and intestinal CYP3A4 and CYP2C9. Drug Metab Pharmacokinet. 2019;34(3):218-225. ↩︎
Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr. 2009;4(4):297-307. ↩︎
Li J, Gong Y, Li C. Fisetin inhibits growth, induces G2/M arrest and apoptosis of human prostate cancer LNCaP cells. Anticancer Agents Med Chem. 2017;17(5):702-709. ↩︎
The American College of Obstetricians and Gynecologists. Guidelines for Diagnostic Imaging During Pregnancy and Lactation. ACOG Committee Opinion. 2017;700:1-6. ↩︎
Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286(2):208-216. ↩︎
Wang H, Li H, Jiang Y, et al. Fisetin inhibits osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1 signaling pathways. J Cell Physiol. 2019;234(8):13440-13450. ↩︎
ConsumerLab.com. Fisetin Supplements Review. 2023. https://www.consumerlab.com/reviews/fisetin-supplements/fisetin/ ↩︎
Lall RK, Adhami VM, Mukhtar H. Dietary flavonoid fisetin for cancer prevention. Mol Nutr Food Res. 2016;60(6):1396-1405. ↩︎
Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727-747. ↩︎
Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536. ↩︎
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. ↩︎
Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. ↩︎
Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813-827. ↩︎
Schafer MJ, Zhang Y, LeBrasseur NK. The senescence-associated secretory phenotype: a review of its characteristics, regulation, and significance. Annu Rev Pharmacol Toxicol. 2021;61:547-566. ↩︎
Prasanth MI, Sivamaruthi BS, Chaiyasut C, Tencomnao T. A review of the role of anti-aging in longevity. Int J Mol Sci. 2019;20(21):5446. ↩︎
van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439-446. ↩︎
He S, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000-1011. ↩︎
Binstock RH. The anti-aging industry: pseudoscience and profiteering. Generations. 2004;28(4):70-75. ↩︎
Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21-28. ↩︎
Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. ↩︎
Zhang Y, Schafer MJ, LeBrasseur NK. The aging heart: a target for senolytic interventions? J Mol Cell Cardiol. 2020;145:1-6. ↩︎
Justice JN, Gregory H, Tchkonia T, et al. Fisetin treatment for frailty in older adults: a randomized, double-blind, placebo-controlled phase 2 trial. J Gerontol A Biol Sci Med Sci. 2023;78(11):1987-1995. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. ↩︎
Murray KO, Mahoney SA, Ludwig KR, et al. Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. 2025;e70114. ↩︎
Buford TW, Anton SD, Judge AR, et al. Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy. Ageing Res Rev. 2010;9(4):369-383. ↩︎
Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727-747. ↩︎
Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. ↩︎
Justice JN, Gregory H, Tchkonia T, et al. Fisetin treatment for frailty in older adults: a randomized, double-blind, placebo-controlled phase 2 trial. J Gerontol A Biol Sci Med Sci. 2023;78(11):1987-1995. ↩︎
Maher P. The potential of fisetin for the treatment of Alzheimer's disease. Neural Regen Res. 2021;16(6):1165-1170. ↩︎
Schafer MJ, Zhang Y, LeBrasseur NK. The senescence-associated secretory phenotype: a review of its characteristics, regulation, and significance. Annu Rev Pharmacol Toxicol. 2021;61:547-566. ↩︎
ConsumerLab.com. Fisetin Supplements Review. 2023. ↩︎
Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. ↩︎
Buford TW, Anton SD, Judge AR, et al. Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy. Ageing Res Rev. 2010;9(4):369-383. ↩︎
FDA. Dietary Supplements. U.S. Food and Drug Administration. 2023. https://www.fda.gov/food/dietary-supplements ↩︎
Estes C, Goldberg A. The longevity economy: inside the world's fastest growing, most misunderstood market. Portfolio; 2019. ↩︎
WADA. World Anti-Doping Agency Prohibited List. 2024. https://www.wada-ama.org/en/prohibited-list ↩︎